CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 474 enrolled
Drug / intervention
dorzolamide hydrochloride (+) timolol maleate +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00449956
NCT00449956Phase 3Completed
CompareCT.gov

Multicenter, Double-Blind, Active Comparator-controlled Study to Evaluate the Safety and Efficacy of MK0507A in Patients With Glaucoma and Ocular Hypertension Who Are Inadequately Controlled on Beta-Blockers

Merck Sharp & Dohme LLC·interventional·Posted Mar 21, 2007·Updated Jun 20, 2017

In Brief

A Phase 3 clinical trial evaluating dorzolamide hydrochloride (+) timolol maleate, Comparator: timolol maleate, and 1 other intervention for Glaucoma. Completed, enrolled 474 participants.

Detailed Summary

The clinical study compares safety and efficacy of MK0507A (dorzolamide 1.0% / timolol 0.5%) with 1) timolol 0.5% and with 2) concomitant therapy with dorzolamide 1.0% / timolol 0.5% in patients with glaucoma and ocular hypertension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 21, 2007
Enrollment StartMar 12, 2007
Primary CompletionFeb 16, 2008
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 19.3 years ago

Interventions

dorzolamide hydrochloride (+) timolol maleatedrug

Dorzolamide hydrochloride 1% + timolol 0.5%, 8-week

Comparator: timolol maleatedrug

timolol maleate 0.5%, 8-week

Comparator: dorzolamide hydrochloridedrug

dorzolamide hydrochloride 1%, 8-week